Close Menu

Personalis

The company priced about 6.6 million shares of its common stock at $19 per share, and is offering underwriters an option to purchase additional shares from a selling stockholder.

The company's Q2 revenue growth was driven by a 74 percent increase in revenues from the analytical services it provided to the VA MVP program.

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.

The company said Q1 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.

The firms are pairing Personalis' comprehensive cancer genomics technology with Indivumed's multiomic database, hoping to improve the insights gleaned from banked samples.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.